AstraZeneca
Market Cap
UK£91.6b
Last Updated
2021/03/02 20:22 UTC
Data Sources
Company Financials +
Executive Summary
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. More Details
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential average dividend payer.
Similar Companies
Share Price & News
How has AstraZeneca's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AZN is less volatile than 75% of UK stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: AZN's weekly volatility (3%) has been stable over the past year.
Market Performance
7 Day Return
-3.6%
AZN
-2.4%
GB Pharmaceuticals
-0.2%
GB Market
1 Year Return
-4.1%
AZN
-10.9%
GB Pharmaceuticals
1.1%
GB Market
Return vs Industry: AZN exceeded the UK Pharmaceuticals industry which returned -9.9% over the past year.
Return vs Market: AZN underperformed the UK Market which returned 2% over the past year.
Shareholder returns
| AZN | Industry | Market | |
|---|---|---|---|
| 7 Day | -3.6% | -2.4% | -0.2% |
| 30 Day | -8.2% | -8.9% | 3.6% |
| 90 Day | -13.3% | -12.4% | 4.2% |
| 1 Year | -1.4%-4.1% | -7.5%-10.9% | 7.0%1.1% |
| 3 Year | 57.4%43.5% | 30.8%16.8% | 10.6%-2.7% |
| 5 Year | 103.6%69.7% | 52.2%23.5% | 40.5%13.4% |
Long-Term Price Volatility Vs. Market
How volatile is AstraZeneca's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall St
Can AstraZeneca PLC's (LON:AZN) ROE Continue To Surpass The Industry Average?2 weeks ago | Simply Wall St
Here's Why AstraZeneca (LON:AZN) Can Manage Its Debt Responsibly3 weeks ago | Simply Wall St
Did You Participate In Any Of AstraZeneca's (LON:AZN) Fantastic 121% Return ?Valuation
Is AstraZeneca undervalued compared to its fair value and its price relative to the market?
49.4%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AZN (£68.8) is trading below our estimate of fair value (£135.97)
Significantly Below Fair Value: AZN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AZN is good value based on its PE Ratio (39.4x) compared to the GB Pharmaceuticals industry average (40x).
PE vs Market: AZN is poor value based on its PE Ratio (39.4x) compared to the UK market (24x).
Price to Earnings Growth Ratio
PEG Ratio: AZN is poor value based on its PEG Ratio (1.7x)
Price to Book Ratio
PB vs Industry: AZN is overvalued based on its PB Ratio (8.1x) compared to the GB Pharmaceuticals industry average (4.5x).
Next Steps
Future Growth
How is AstraZeneca forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?
22.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AZN's forecast earnings growth (22.7% per year) is above the savings rate (1%).
Earnings vs Market: AZN's earnings (22.7% per year) are forecast to grow slower than the UK market (23.2% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AZN's revenue (10.4% per year) is forecast to grow faster than the UK market (7.3% per year).
High Growth Revenue: AZN's revenue (10.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AZN's Return on Equity is forecast to be very high in 3 years time (44.7%).
Next Steps
Past Performance
How has AstraZeneca performed over the past 5 years?
-7.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AZN has a large one-off gain of $977.0M impacting its December 31 2020 financial results.
Growing Profit Margin: AZN's current net profit margins (12%) are higher than last year (5.5%).
Past Earnings Growth Analysis
Earnings Trend: AZN's earnings have declined by 7.7% per year over the past 5 years.
Accelerating Growth: AZN's earnings growth over the past year (139%) exceeds its 5-year average (-7.7% per year).
Earnings vs Industry: AZN earnings growth over the past year (139%) exceeded the Pharmaceuticals industry 23.6%.
Return on Equity
High ROE: Whilst AZN's Return on Equity (20.1%) is high, this metric is skewed due to their high level of debt.
Next Steps
Financial Health
How is AstraZeneca's financial position?
Financial Position Analysis
Short Term Liabilities: AZN's short term assets ($19.5B) do not cover its short term liabilities ($20.3B).
Long Term Liabilities: AZN's short term assets ($19.5B) do not cover its long term liabilities ($30.8B).
Debt to Equity History and Analysis
Debt Level: AZN's debt to equity ratio (140.9%) is considered high.
Reducing Debt: AZN's debt to equity ratio has increased from 81.2% to 140.9% over the past 5 years.
Debt Coverage: AZN's debt is well covered by operating cash flow (21.8%).
Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (6.3x coverage).
Balance Sheet
Next Steps
Dividend
What is AstraZeneca current dividend yield, its reliability and sustainability?
2.92%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: AZN's dividend (2.92%) is higher than the bottom 25% of dividend payers in the UK market (1.47%).
High Dividend: AZN's dividend (2.92%) is low compared to the top 25% of dividend payers in the UK market (4.52%).
Stability and Growth of Payments
Stable Dividend: AZN's dividends per share have been stable in the past 10 years.
Growing Dividend: AZN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (114.9%), AZN's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: AZN's dividends in 3 years are forecast to be well covered by earnings (39.5% payout ratio).
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
7.8yrs
Average management tenure
CEO
Pascal Soriot (61 yo)
8.42yrs
Tenure
US$21,089,782
Compensation
Mr. Pascal Soriot, M.B.A., D.V.M., had been Independent Non-Executive Director at CSL Limited since August 19, 2020 until January 31, 2021. Mr. Soriot has been the Chief Executive Officer and Executive Dir...
CEO Compensation Analysis
Compensation vs Market: Pascal's total compensation ($USD21.09M) is above average for companies of similar size in the UK market ($USD4.12M).
Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 8.42yrs | US$21.09m | 0.018% $ 16.4m | |
| CFO & Executive Director | 7.33yrs | US$10.52m | 0.013% $ 12.1m | |
| Executive Vice-President of Operations & Information Technology | 5.75yrs | no data | no data | |
| Head of Investor Relations | no data | no data | no data | |
| Executive VP of Human Resources & General Counsel | 12.17yrs | no data | no data | |
| Executive VP of Sustainability & Chief Compliance Officer | 9.67yrs | no data | no data | |
| Executive Vice-President of BioPharmaceuticals Research & Development | 8.17yrs | no data | no data | |
| Executive Vice-President of BioPharmaceuticals Business Unit | 8.17yrs | no data | no data | |
| Senior VP and Head of Research | no data | no data | no data | |
| Chief Adviser | 4.5yrs | no data | no data | |
| Executive VP of International & China President | 7.17yrs | no data | no data | |
| Executive Vice-President of Europe & Canada | 3.92yrs | no data | no data |
7.8yrs
Average Tenure
57.5yo
Average Age
Experienced Management: AZN's management team is seasoned and experienced (7.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 8.42yrs | US$21.09m | 0.018% $ 16.4m | |
| CFO & Executive Director | 7.33yrs | US$10.52m | 0.013% $ 12.1m | |
| Non-Executive Director | 21.92yrs | US$140.63k | 0.0046% $ 4.2m | |
| Independent Non-Executive Chairman | 8.75yrs | US$952.98k | 0.0030% $ 2.7m | |
| Independent Non-Executive Director | 3.92yrs | US$202.06k | 0.00054% $ 494.8k | |
| Senior Independent Non-Executive Director | 2.17yrs | US$192.51k | 0.00023% $ 210.8k | |
| Independent Non-Executive Director | 1.5yrs | US$170.66k | 0.00015% $ 137.5k | |
| Independent Non-Executive Director | 3.25yrs | US$147.45k | 0.000080% $ 73.3k | |
| Independent Non-Executive Director | 3.42yrs | US$167.93k | 0.00013% $ 119.1k | |
| Independent Non-Executive Director | 8.92yrs | US$150.18k | 0.00016% $ 146.6k | |
| Independent Non-Executive Director | 2.17yrs | US$140.63k | 0.000080% $ 73.3k | |
| Independent Non-Executive Director | 3.75yrs | US$161.11k | 0.000080% $ 73.3k |
3.8yrs
Average Tenure
61yo
Average Age
Experienced Board: AZN's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: AZN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
AstraZeneca PLC's company bio, employee growth, exchange listings and data sources
Key Information
- Name: AstraZeneca PLC
- Ticker: AZN
- Exchange: LSE
- Founded: 1992
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£91.634b
- Shares outstanding: 1.31b
- Website: https://www.astrazeneca.com
Number of Employees
Location
- AstraZeneca PLC
- 1 Francis Crick Avenue
- Cambridge Biomedical Campus
- Cambridge
- Cambridgeshire
- CB2 0AA
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| AZN | NasdaqGS (Nasdaq Global Select) | SPONSORED ADR | US | USD | May 1993 | |
| AZNC.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | May 1993 |
| AZN | LSE (London Stock Exchange) | Yes | Ordinary Shares | GB | GBP | May 1993 |
| AZN | OM (OMX Nordic Exchange Stockholm) | Yes | Ordinary Shares | SE | SEK | May 1993 |
| AZN N | BMV (Bolsa Mexicana de Valores) | SPONSORED ADR | MX | MXN | May 1993 | |
| 0A4J | LSE (London Stock Exchange) | SPONSORED ADR | GB | USD | May 1993 | |
| ZEG | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | May 1993 |
| ZEGA | DB (Deutsche Boerse AG) | SPONSORED ADR | DE | EUR | May 1993 | |
| AZNS | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | SEK | May 1993 |
| ZEG | XTRA (XETRA Trading Platform) | Yes | Ordinary Shares | DE | EUR | May 1993 |
| AZN | SWX (SIX Swiss Exchange) | Yes | Ordinary Shares | CH | CHF | May 1993 |
| AZNL | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | Ordinary Shares | GB | GBP | May 1993 |
| AZN | BASE (Buenos Aires Stock Exchange) | CEDEAR EACH REP 0.5 ADR USD0.25 | AR | ARS | Dec 2003 |
Biography
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastro...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/03/02 20:22 |
| End of Day Share Price | 2021/03/02 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.